The CheckMate 498 prospective phase III randomized clinical trial compared the Stupp regimen with temozolomide (TMZ) replacement with nivolumab (NIVO) in newly diagnosed GBM patients with negative methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter region. The gene discussed is MGMT; the disease is glioblastoma.